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Ergot-induced disease in humans was known long before Biblical times and has been the
root cause for countless human epidemics spanning from the early fourteenth century
to the late sixteenth century. In contrast, many of these same ergot alkaloids have
been utilized for their medicinal properties to mitigate migraine headaches and have had
indications as anti-carcinogens. Although ergot alkaloids have been used for centuries
by humans, basic pharmacokinetic data has not been documented for clinical disease in
livestock. Consequently, a threshold dose and accurate dose-response data have yet to be
established. Throughout the past several years, new detection techniques have emerged
to detect these alkaloids at the parts per billion (ppb) level which has allowed for new
efforts to be made with respect to determining threshold levels and making accurate
clinical diagnoses in affected animals. This perspectives article provides a critical initial
step for establishing a uniform interpretation of ergot toxicosis from limited existing data.
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INTRODUCTION
Ergot alkaloids are made as secondary metabolites of fungi. Their
production occurs in the sclerotia of several species of the genus
Claviceps, the most common being Claviceps purpurea. These
compounds belong to the family of indole alkaloids, one of the ten
classes of alkaloids that pharmacologists have defined from plant
secondary metabolites. Lysergic acid, a tetracycline ergoline ring
system, is a common structure to all of the ergot alkaloids (Krska
et al., 2008). The chemical structure of ergotamine, the most
commonly found ergot alkaloid and the one responsible for the
clinical disease known as ergot, has been documented in a clas-
sic text (Matossian, 1989; Bennett and Bentley, 1999; Council for
Agricultural Science and Technology, 2003). Other major alka-
loids detected in ergot sclerotia include ergocornine, ergocristine,
ergosine, and ergonovine, and α-ergocryptine (Krska et al., 2008;
Wallwey and Li, 2011; Takach and Young, 2014; also see Figure 1,
the chromatogram).
Historically, ergot alkaloids have had a large impact on soci-
eties. They are likely the cause for the last of the 10 plagues of
Egypt; it is believed that many of the oldest sons succumbed
following the opening of grain and storage facilities whose con-
tents were contaminated by theClaviceps fungi (Marr andMalloy,
1996). Accounts from the Middle Ages describe “St. Anthony’s
fire,” a symptom of intense inflammation attributed to human
consumptions of food prepared with ergot-contaminated rye.
Furthermore, Marie Antoinette’s comment, “Let them eat cake,
not bread,” most likely surfaced because of ergot contaminated
rye bread which was a common food among peasants.
Currently, modern grain cleaning techniques have elimi-
nated ergotism as a human disease, but it remains a significant
and devastating disease in the veterinary field primarily affect-
ing sheep, cattle, pigs, and chickens. Clinical signs of ergotism
in animals include gangrenous extremities, abortion, convul-
sions, agalactia, and ataxia (Lorenz and Hoseney, 1979; Richard,
2007; Duringer et al., 2012). Agalactia and the loss of ears,
tails, and hooves are common sequelae seen in animals due
to vasoconstriction: ergot alkaloids affect the supply of blood
to the extremities of the body in addition to acting directly
on the central nervous system via the pituitary where they
activate the D2 dopamine receptors (Oliver, 2005; Richard,
2012). The tetracyclic ergoline ring of ergot alkaloids is sim-
ilar to the structure of biogenic amines (Eckert et al., 1978),
allowing them to act on the dopaminergic (Larson et al.,
1999), serotonergic (Dyer, 1993; Schöning et al., 2001), and
α-adrenergic receptors (Oliver et al., 1998; Schöning et al.,
2001). Most recently, plant agronomists have shown different
varieties within a plant species can portray different “chemo-
types” or constitutions different alkaloids (Wallwey and Li,
2011; Panaccione et al., 2012, 2014; Takach and Young, 2014).
Sclerotia show significant differences in their total alkaloid con-
tent, varying between 0.01 and 0.05% (Krska and Crews, 2008).
Patterns that occur in alkaloid production are attributed to
an individual strain in a geographic region (Krska and Crews,
2008).
In the United States, there is no regulatory limit defined for
ergot alkaloids in grain. In Europe, while there are discussions on
establishing legal limits, the European Food Safety Agency (EFSA)
at this time has not recommended a limit other than 0.03–3.6
and 0.6μg/kg b.w. per day for children and adults, respectively
(European Food Safety Authority, 2012).
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FIGURE 1 | HPLC fluorescence chromatogram of ergot alkaloids, both pure standards and extracted feed sample containing ergot bodies (Craig et al.,
2014).
Two types of ergotism have been described: gangrenous (vaso-
constrictive) and convulsive (neurological and abortogenic) (da
Rocha et al., 2014). Though these two designations exist, the eti-
ology of both is rooted in the vasoconstrictive ability of ergot
alkaloids. Associating each alkaloid with a vasoconstrictive mea-
surement (bovine lateral saphenous vein contractile response) has
been a key factor in an accurate evaluation of clinical disease and
will be discussed in Table 1.
The Endophyte Service Laboratory (ESL) (Craig et al., 1994,
2014), along with others (Rottinghaus et al., 1993; Saiga, 1998;
Miyazaki, 2004), has conducted studies on threshold levels of
alkaloids associated with tall fescue toxicosis. Moreover, these
studies have been related to clinical signs as seen in fescue toxico-
sis (Brendemuehl et al., 1995; Blodgett, 2001; Tor-Agbidye et al.,
2001; Marin et al., 2013). In contrast, few studies have been done
on ergot-derived alkaloids to establish a threshold in livestock
for ergotism. Thus, this article discusses the known correlations
between the ergot alkaloids and development of ergotism in
clinical cases to serve as a starting point for suggesting threshold
levels and metabolism of these toxicants.
METHODS
EXTRACTION OF THE ERGOT ALKALOIDS
A method for extraction of ergot alkaloids from plant material
was developed based on previous studies, for subsequent anal-
ysis by HPLC-fluorescence (Rottinghaus et al., 1991; Hill et al.,
1993; Craig et al., 1994; Duringer et al., 2012). A standardmixture
comprised of ergonovine, ergosine, ergotamine, ergocornine, α-
ergocryptine, and ergocristine was purchased from Romer Labs,
Inc. (Union, MO, USA). Seed, straw, hay, or feed pellet sam-
ples were ground in a Cyclotec 1093 sample mill and passed
through a 0.5-mm screen. To each tube, one gram of sample,
11mL of chloroform and 1mL of 0.001M NaOH were added
and mixed for 18–24 h in the dark, then centrifuged at 650 ×
g. Five milliliters of supernatant was applied to a 500mg/6mL
solid phase extraction (SPE) column containing 0.5 g Ergosil®
and 0.5 g anhydrous sodium sulfate. The ergot alkaloids were
extracted by adding 5mL eluent to the SPE, followed by a
2mL 4:1 acetone:chloroform (v/v) wash and elution with 2.5mL
methanol. The eluent was dried under nitrogen at 50◦C, then
reconstituted in 0.5mL methanol. Samples were mixed for 10 s,
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Table 1 | Concentration at onset of contractile response, half maximal effective concentration or potency (EC50), and the maximal response or
efficacy (EMAX) of ergot alkaloids in bovine lateral saphenous veinsa.
Alkaloid Onset (M)b EC50 (M) EMAX (%) Ergotamine equivalence level
Ergovaline 1 × 10−8 4.0 × 10−6 ± 1.5 × 10−6 104.1±6.0 1
Ergotamine 1 × 10−8 4.0 × 10−6 ± 1.5 × 10−6 104.1±6.0 1
Ergonovine 1 × 10−7 3.4 × 10−6 ± 8.8 × 10−7 68.5±4.1 0.1
Ergocristine 1 × 10−7 5.6 × 10−6 ± 1.3 × 10−6 45.5±4.5 0.1
Ergocornine 1 × 10−7 4.0 × 10−5 ± 2.3 × 10−5 57.2±9.9 0.1
α-Ergocryptine 1 × 10−6 5.4 × 10−6 ± 1.2 × 10−6 42.9±4.1 0.01
Lysergic acid 1 × 10−5 5.5 × 10−5 ± 2.3 × 10−5 22.6±4.1 0.001
aTaken from Klotz et al. (2006, 2007, 2010).
bExpressed as a percent of norepinephrine maximum, which was a 1 × 10−4 M norepinephrine reference addition. Onset is normalized to the closest order of
magnitude.
sonicated for 10 s, and centrifuged at 650 × g for 5min then
analyzed via HPLC-fluorescence.
HPLC-FLUORESCENCE ANALYSIS FOR ERGOT ALKALOIDS
Reverse-phase HPLC analysis is coupled with fluorescence detec-
tion (excitation and emission wavelengths of 250 nm and 420 nm,
respectively) and a gradient run at 0.9mL/min. Mobile phases
of 1mM ammonium carbonate (A) and ACN (B) were pro-
grammed as follows: equilibrate from 0 to 5min at 75% A,
then decrease linearly to 65% A from 5 to 15min, hold at
65% A from 15 to 20min, then decrease linearly to 25% A
from 20 to 25min. A Gemini 3.0 μ C18 110Å (Phenomenex,
Torrance, CA) column was used in conjunction with a guard col-
umn cartridge of similar packing. Figure 1 shows an example
of a HPLC-fluorescence chromatogram for ergonovine, ergo-
sine, ergotamine, ergocornine, α-ergocryptine, and ergocristine
produced using this assay. [Ergonovine and the epimers of
the other ergot alkaloids are not retained by the Ergosil® SPE
columns (reference Krska et al., 2008) and are not included
in reporting the total ergot alkaloid content of the feed
sample]. The method performance has a limit of detection
(LOD) of 11 ppb for ergosine, ergotamine, and ergocornine,
13 ppb for α-ergocryptine, and 14 ppb for ergocristine. The
limit of quantitation (LOQ) is 39 ppb for ergosine and ergo-
tamine, 41 ppb for ergocornine, 49 ppb α-ergocryptine, and
50 ppb for ergocristine. Within day/Day to day variations are
8.5%/6.5% for ergosine and ergotamine, 4.5%/6.9% for ergo-
cornine, 5.8%/7.8% for α-ergocryptine, and 6.8%/10.6% for
ergocristine. The recovery for the above-mentioned alkaloids is
92–97%.
WHATWE KNOW ABOUT VASOCONSTRICTION AND
ABORTION FROM ERGOT ALKALOIDS
Using the data presented in Klotz et al. (2006, 2007, 2010, 2011),
we have constructed Table 1, which summarizes the vascular
potency and efficacy of ergovaline (the predominant ergot alka-
loid found in tall fescue), ergotamine, ergonovine, ergocristine,
ergocornine, ergocryptine, and lysergic acid in relative terms.
Table 1 bridges what is known in tall fescue toxicosis, i.e., vaso-
constriction and the extrapolated abortogenic sequelae. It should
be noted that the principal column evaluated in determining
the onset of vasoconstriction in clinical disease is column two
[Onset (M)].
As Table 1 emphasizes, ergovaline and ergotamine have
equal sensitivity for vasoconstriction, whereas ergonovine,
ergocristine, and ergocornine are about one-tenth as powerful.
Pharmacologically, the half-maximal concentration (EC50) and
the onset concentration are measures of a compound’s potency
(the lower the concentration the more potent the compound);
ergotamine and ergovaline are identical in this aspect. The onset
of vasoconstriction is reported in concentration (moles/L), and is
viewed as the best indicator of toxicosis when evaluating levels in
feedstuffs. Interpreting the chromatogram in Figure 1 in relation
to the additive effects of all ergot alkaloids present is performed
by utilizing a multiplicative factor in front of various alkaloids;
therefore, 10 ergonovine molecules are equally vasoconstrictive
to one ergovaline molecule. More recently, Klotz et al. (2013) has
demonstrated that the EC50 for ergovaline, ergotamine, and ergo-
cornine can be reduced by an animal’s prior exposure to ergot
alkaloids. This may have an influence on the animal’s perceived
sensitivity (as reported by the clinician/researcher) andmay affect
the threshold of an individual animal (Pesqueira et al., 2014).
Further, severe winters and wet springs (wet and cold weather
patterns in general) have been shown to be more conducive to
ergot-related disease (Welty et al., 1994). This strong correla-
tion between weather and ergot disease is easily seen throughout
historical events and in our own clinical cases below (Table 2).
CORRELATION OF ERGOT TOXINS WITH CLINICAL DISEASE
The alkaloids that cause fescue foot and summer slump syndrome
are produced by fungi in pasture grasses. Because of similar
vasoconstrictive abilities of ergovaline and ergotamine, we have
correlated some of the studies done with fescue with what we
have seen from clinical cases with ergot. Field and barn studies of
natural fescue foot and herds have been conducted (Oliver, 2005;
Marin et al., 2013). Therefore, we are illustrating typical cases seen
in feed sample submissions over the last 2–3 years to the ESL in
Oregon.
In Table 2, column 2 represents the total alkaloids observed,
which include a summation of all six ergot alkaloids. Since
different alkaloids have different vasoconstrictive onset values,
column 3 relates the six alkaloids (Table 1) back to “ergotamine
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Table 2 | Clinical evaluation of ergot toxicosis in cattle with
ergotamine equivalence levels (ppb) in feed on a dry weight basis.
Case
number
Total ergot
level
observed
(ppb)a
Ergotamine
equivalence
level (ppb)
Weather
conditions
Clinical signs
observed
a 473 473 −20◦C, Canada,
February
Tail loss
b 1500 415 1◦C, Oregon,
December
Moderate
lameness
c 2909 466 −2◦C, Idaho,
January
Decreased feed
intake
d 3555 778 −5◦C, E.
Oregon,
February
Early term
abortions, low
milk yield
e 5999 626 −5◦C, Idaho,
January
No feed
consumption
f 11,538 1161 −4◦C, Canada,
April
Sloughing of
hooves
g 54,916 3728 1◦C, Oregon,
January
Early term
abortions
h 62,245 10,124 −1◦C, Idaho,
January
Hooves
sloughing
completely off
aIncludes ergonovine, ergosine, ergotamine, ergocornine, α-ergocryptine, and
ergocristine.
equivalents.” Therefore, ergotamine equivalents are correlated to
clinical signs (column 5).
Eight examples of clinical cases associated with feed samples
submitted to the ESL by veterinarians suspecting ergot toxico-
sis are shown to illustrate typical cases that have been seen. The
ESL consults with veterinarians and evaluates all aspects of the
case to determine if testing of feed samples is warranted. If so,
results are often discussed with the client to ensure that proper
measures are taken to resolve ergot toxicosis. Five to ten years
ago the ESL would observe ergot cases approximately once per
month; however, this has progressed to several cases per week and
sometimes multiple cases each day in recent years despite main-
taining approximately the same number of total samples tested.
Our worst toxicosis cases have been in cattle and horses. The
increase in cases seen in the Pacific Northwest and throughout the
country is likely due to climate change or the lack of field burning
that has been phased out throughout the years. The stoppage of
burning has greatly reduced the ability to destroy C. purpurea by
fire.
Evaluation of the cases included in Table 2 is as follows:
The following cases in cattle involved pellets as nearly 100%
of the provided feed source, with the exclusion of case b, which
used a grass seed sample. Pellets were usually a combination of
grass seed with additional alfalfa or other hay sources mixed in.
In cases f and h, cattle had exposure to overgrazed pasture, and it
is estimated that little nutrition came from the pasture sources. In
both cases, the pellet mixture comprised most of the usable diet.
The first case (a) presents an ergotamine level of nearly 500
parts per billion (ppb). This case originated in February when
the colder weather prompted vasoconstriction in the extremi-
ties, specifically, the tissue around the tail to become necrotic. No
sloughing of ears were observed nor reported in this particular
case.
The second case (b) reported 1500 ppb ergot alkaloids and
occurred in December as the feed bunks were being cleaned out.
There was moderate lameness and some necrosis about the feet.
The 1500 ppb consisted of ergotamine and ergocornine, resulting
in a lower ergotamine equivalence level (415 ppb) that was similar
to case (a).
The third case (c) revealed approximately 2900 ppb ergot alka-
loids in pellets which triggered a decreased consumption in feed,
as well as a necrotic area around the coronet band of the hoof.
This outcome was observed in steers in January. Ergotamine,
ergocornine, and ergocryptine were found in the feed. The ergo-
tamine equivalence level (466 ppb) illustrated similarities to that
of case (a).
The fourth case (d) presented nearly 3500 ppb ergot alkaloids
and took place in February. This case showed greater severity of
clinical signs, i.e., term abortions, agalactia, and reduced milk
production in the dairy herd. This case had a 778 ppb ergotamine
equivalence level.
The fifth case (e) presented itself in January and had a total
ergot alkaloid concentration of 6000 ppb. The animals refused
to consume any feed, resulting in near starvation. This case was
composed of very little ergotamine and mostly other ergot alka-
loids, which dramatically brought the ergotamine equivalence
level down to 626 ppb.
The sixth case (f) occurred during April, with ergot alkaloid
levels measuring almost 12,000 ppb. The steers exhibited slough-
ing of the hooves, tails, and ears. So many animals sloughed their
hooves that approximately 40% of the herd had to be termi-
nated. This case consisted of multiple ergot alkaloids and had an
ergotamine equivalence level of approximately 1000 ppb.
The seventh case (g) was the second highest case of total ergot
alkaloids (54,916 ppb) that we have observed and occurred in
January. Though the weather was fairly warm and dry, there were
early term abortions in a high percentage of the cow-calf opera-
tion. Approximately 45–47 of the 59 animals that were pregnant
had early term abortions over a 2 week period. This case had an
approximate 4000 ppb ergotamine equivalence level.
The eighth (h) and final case entailed the observance of cattle
during January in the northern region of the United States. This
case produced approximately 62,000 ppb of total ergot alkaloids.
The clinical consequences of the ergot alkaloids resulted in 3/4 of
the cow’s hooves to slough off, after which the animals had to be
sacrificed. This case consisted of both ergotamine and other ergot
alkaloids, and had an ergotamine equivalence level to approx-
imately 10,000 ppb. Although the weather was warm, the high
concentration of ergot alkaloid induced enough vasoconstriction
to clinically affect the animals.
The bioavailability and pharmacokinetic data of ergot
alkaloids in cattle are limited and affected by many different
factors. However, using the highest and the lowest dietary ergo-
tamine concentrations reported in Table 2, calculations were
done to illustrate a theoretical relationship with the ergo-
tamine concentration in a feedstuff and a maximum potential
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concentration in blood. A feedstuff containing the lowest con-
centration of 473 ppb (case a) or 0.473mg/kg ergotamine fed
to a 500 kg cow consuming 2.5% of BW will consume a total
of 5.9mg of ergotamine per day. Assuming that the ergotamine
is 100% bioavailable from the feedstuff (not always the case as
this is negatively correlated with the maturity of the feedstuff),
100% absorbed (not always the case, as these compounds are
likely biotransformed by gut microbes prior to absorption), 100%
bioavailable in the blood (assuming negligible bioaccumulation
in tissues or initial hepatic detoxification) and total blood vol-
ume of 55mL/kg of BW, a maximum ergotamine concentration
ever reaching the blood would be 0.215μg ergotamine/mL of
blood. Although this is far below the EC50 reported for ergo-
tamine in Table 1 of 4 × 10−6 M or an approximate of 2.32μg
of ergotamine/mL in blood, it is much higher than the corre-
sponding onset concentration for ergotamine of 1 × 10−8 M or
0.005μg /mL. If we substituted the highest reported ergotamine
concentration in Table 2 (case h), the maximum concentration of
ergotamine that could ever reach the blood is 4.6μg /mL. This
is twice the concentration of the EC50 of ergotamine and could
easily explain the severe clinical signs observed.
The data that resulted from these clinical cases illustrate that
ergot alkaloids can cause vasoconstriction and deleterious con-
sequences regardless of seasonal conditions (Egert et al., 2014).
Severe vasoconstriction will cause the hooves to slough off and/or
abortions. However, in cooler or freezing weather, the values
for the vasoconstrictiveness of the different ergot alkaloids are
not dissimilar from what is found in endophyte-infected tall fes-
cue with the predominant ergot alkaloid ergovaline (Duringer
et al., 2012; Foote et al., 2012). This observation should be doc-
umented in future scientific studies. As for now, there have been
no specific studies looking at individual alkaloids other than the
physiometry values documenting vasoconstriction. Furthermore,
there have been no studies related to the convulsive aspect of this
disease (neurological and abortogenic) and the individual alka-
loids. The only clinical evaluation conducted has been by the
papers from Klotz et al. (2006, 2007, 2008, 2010). These papers
examine the onset of vasoconstriction. Threshold levels have yet
to be established for different animal species. When consider-
ing the international transportation of feed, ergot levels become
an important factor to evaluate in developing Food Safety stan-
dards and programs. In particular, feed produced in the European
continent and transported to the Middle East are susceptible to
C. purpurea due to the wet springs and summers that promote
fungal growth.
WHAT SHOULD BE DONE IN FUTURE STUDIES?
Though this disease has been known for hundreds of years, only a
paltry amount of information is available to accurately diagnose
disease at a clinical level (where animal production is affected and
animal welfare becomes a concern). The first step in expanding
this information should be establishing the threshold level in dif-
ferent species, particularly cattle and horses that could be exposed
to ergot alkaloids in their feed. It should be noted that over-
seas, camels, goats, and sheep are also frequently exposed to these
toxic alkaloids. The second step is to establish other bio-indicators
of clinical disease other than prolactin levels, weight gain, and
some of the more classical animal observances. Lastly, the vaso-
constrictive and convulsive effects and their subsequent clinical
consequences need to be separated.
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